Qing Yi Selected Research

azaspirane

3/2012	Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
4/2008	A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma.
6/2007	Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Qing Yi Research Topics

Disease

72	Neoplasms (Cancer) 01/2022 - 05/2002
42	Multiple Myeloma 10/2022 - 05/2002
10	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 11/2013 - 06/2007
5	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 06/2012
3	Carcinogenesis 01/2021 - 05/2014
3	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 06/2011
2	Infections 02/2022 - 01/2011
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 06/2007
2	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2019
2	Melanoma (Melanoma, Malignant) 01/2022 - 01/2018
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 10/2010
2	Monoclonal Gammopathy of Undetermined Significance 01/2019 - 10/2018
2	Neoplasm Metastasis (Metastasis) 10/2018 - 01/2015
2	Bone Resorption 08/2017 - 01/2013
2	B-Cell Lymphoma (Lymphoma, B Cell) 08/2017 - 12/2003
2	Lymphoma (Lymphomas) 09/2013 - 02/2008
2	Diabetic Retinopathy (Retinopathy, Diabetic) 08/2003 - 04/2002
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022
1	T-Cell Leukemia (Leukemia, T Cell) 01/2022
1	Myeloid Leukemia (Leukemia, Myelocytic) 01/2022
1	Obesity 01/2021
1	Kidney Diseases (Kidney Disease) 01/2019
1	Anemia 01/2019
1	Paraproteinemias (Monoclonal Gammopathy) 01/2019
1	Splenomegaly 01/2019
1	Plasma Cell Neoplasms 01/2019
1	Adenocarcinoma of Lung 10/2018

Drug/Important Bio-Agent (IBA)

15	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2002
12	AntigensIBA 12/2021 - 05/2002
12	VaccinesIBA 01/2018 - 12/2005
8	Bortezomib (Velcade)FDA Link 01/2022 - 06/2009
6	Pharmaceutical PreparationsIBA 01/2020 - 01/2011
5	CytokinesIBA 01/2021 - 06/2011
5	LigandsIBA 01/2018 - 01/2011
5	Monoclonal AntibodiesIBA 04/2015 - 10/2006
5	Interleukin-6 (Interleukin 6)IBA 01/2015 - 12/2006
4	Interleukin-9 (Interleukin 9)IBA 01/2022 - 11/2012
4	Chimeric Antigen ReceptorsIBA 12/2021 - 03/2014
4	p38 Mitogen-Activated Protein KinasesIBA 12/2017 - 03/2006
4	AntibodiesIBA 08/2017 - 04/2008
4	Lenalidomide (CC 5013)FDA Link 11/2015 - 09/2009
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 01/2020
3	Adenosine Triphosphate (ATP)IBA 12/2021 - 01/2016
3	Peptides (Polypeptides)IBA 01/2021 - 09/2011
3	Interleukin-33IBA 01/2019 - 01/2018
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 09/2014 - 12/2005
3	Cyclin D1IBA 06/2012 - 02/2008
3	azaspiraneIBA 03/2012 - 06/2007
3	Neoplasm Antigens (Tumor Antigens)IBA 10/2009 - 12/2003
2	carfilzomibIBA 01/2022 - 11/2013
2	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 02/2008
2	Proteasome InhibitorsIBA 01/2022 - 03/2012
2	InterferonsIBA 12/2021 - 05/2014
2	CholesterolIBA 01/2021 - 01/2019
2	LipidsIBA 01/2020 - 04/2010
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 10/2019 - 09/2015
2	MicroRNAs (MicroRNA)IBA 01/2019 - 01/2018
2	Immunoglobulin G (IgG)IBA 01/2019 - 07/2011
2	Conditioned Culture MediaIBA 01/2018 - 10/2014
2	Phosphotransferases (Kinase)IBA 12/2017 - 04/2010
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2016 - 09/2011
2	ChemokinesIBA 09/2015 - 06/2011
2	CateninsIBA 10/2014 - 06/2012
2	HLA-A*02:01 antigenIBA 09/2013 - 09/2011
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 06/2012 - 04/2010
2	Insulin-Like PeptidesIBA 06/2012 - 04/2010
2	Interleukin-4 (Interleukin 4)IBA 09/2010 - 05/2007
2	Rituximab (Mabthera)FDA Link 09/2009 - 02/2008
1	Activated-Leukocyte Cell Adhesion Molecule (Neurolin)IBA 10/2022
1	Immunoglobulins (Immunoglobulin)IBA 02/2022
1	FumaratesIBA 01/2022
1	Poly(amidoamine)IBA 01/2022
1	Angiogenesis InhibitorsIBA 01/2022
1	Oncogene Proteins (Oncogene Protein)IBA 01/2022
1	Cruciform DNA (Holliday Junctions)IBA 01/2021
1	Acetate-CoA Ligase (Acetyl CoA Synthetase)IBA 01/2021
1	Granzymes (Granzyme)IBA 11/2020
1	UbiquitinIBA 01/2020
1	Ligases (Synthetase)IBA 01/2020
1	daratumumabIBA 01/2020
1	Carbon Nanotubes (Carbon Nanotube)IBA 01/2020
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2020
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2020
1	Basigin (Extracellular Matrix Metalloproteinase Inducer (EMMPRIN))IBA 01/2020
1	Polychlorinated Dibenzodioxins (TCDD)IBA 01/2019
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 01/2019
1	Cadherins (E-Cadherin)IBA 11/2018
1	Long Noncoding RNAIBA 10/2018
1	3' Untranslated Regions (3' UTR)IBA 01/2018
1	N- (2- amino- 5- fluorobenzyl)- 4- (N- (pyridine- 3- acrylyl)aminomethyl)benzamideIBA 01/2018
1	Immune Checkpoint InhibitorsIBA 01/2018
1	Therapeutic UsesIBA 01/2018

Therapy/Procedure

34	Immunotherapy 01/2022 - 05/2002
20	Therapeutics 02/2022 - 12/2003
7	Drug Therapy (Chemotherapy) 01/2022 - 06/2007
2	Immunomodulation 11/2009 - 06/2003
2	Light Coagulation 08/2003 - 04/2002
2	Lasers (Laser) 08/2003 - 04/2002
1	Cell- and Tissue-Based Therapy (Cell Therapy) 12/2021
1	Biological Therapy 11/2020